ArticleSurgical neurology international2026
Trends in meningioma-related mortality among U.S. adults: A CDC WONDER analysis from 2000 to 2023.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meningiomas are the most common primary intracranial tumors in the United States, comprising nearly 41% of central nervous system tumors. While the majority are benign, atypical (World Health Organization Grade II) and malignant (Grade III) subtypes are clinically significant due to their aggressive biology, higher recurrence, and increased mortality risk. Despite their burden, national mortality trends and demographic disparities in meningioma-related deaths remain underexplored. Methods: We conducted a population-based analysis of meningioma-related mortality among U.S. adults aged ≥65 years from 1999 to 2023 using the centers for disease control and prevention (CDC) wide-ranging online data for epidemiologic research (WONDER) database. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated and stratified by age, sex, race/ethnicity, region, and urbanization. Temporal trends were assessed using Joinpoint regression to estimate annual percent change (APC) with 95% confidence intervals (CIs). Results: From 2000 to 2023, 28,875 meningioma-related deaths were recorded, with higher mortality in males (65.6%) compared to females (34.4%). The overall AAMR declined from 3.79 in 2000 to 2.44 in 2009 (APC -3.86; 95% CI -5.07 to -2.63; Conclusion: Meningioma-related mortality in the United States declined substantially in the early 2000s but has shown an upward trend in recent years, with disparities across sex, race/ethnicity, and region. These findings highlight the need for continued surveillance and targeted public health strategies to address high-risk populations and mitigate the rising mortality associated with aggressive meningioma subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.